Application of small interfering RNA of long non-coding ribonucleic acid MRAK009713 to preparation of drugs for treating neuropathic pain

A technique for MRAK009713 and neuropathic pain, which is applied in the invention field of analgesic drugs for neuropathic pain, and can solve the problem of limited research on long non-coding ribonucleic acid

Active Publication Date: 2015-12-09
NANCHANG UNIV
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, breakthroughs have been made in the research of non-coding RNAs (such as microRNA, siRNA and piRNA

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of small interfering RNA of long non-coding ribonucleic acid MRAK009713 to preparation of drugs for treating neuropathic pain
  • Application of small interfering RNA of long non-coding ribonucleic acid MRAK009713 to preparation of drugs for treating neuropathic pain
  • Application of small interfering RNA of long non-coding ribonucleic acid MRAK009713 to preparation of drugs for treating neuropathic pain

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] The long non-coding ribonucleic acid MRAK009713 small interfering RNA preparation suitable for oral administration, injection, buccal tablet or other local or systemic dosage forms for the treatment of neuropathic pain is prepared by methods known in the art.

Embodiment 2

[0020] Using methods well known in the art, made suitable for P2X 3 The long non-coding ribonucleic acid MRAK009713 small interfering RNA preparation in oral, injection, lozenge or other local or systemic dosage form for the treatment of receptor-mediated related diseases.

[0021] In a word, the long non-coding ribonucleic acid MRAK009713 small interfering ribonucleic acid can be used for oral administration, injection, buccal tablet or other local or systemic dosage forms for the prevention and treatment of the above diseases.

[0022] In order to better understand the essence of the present invention, the following long non-coding ribonucleic acid MRAK009713 small interfering ribonucleic acid pair P2X 3 Experiments and results of receptor-mediated treatment of related diseases to prove the use of long non-coding ribonucleic acid MRAK009713 small interfering ribonucleic acid.

[0023] 1. Materials and methods.

[0024] 1. Animals and groups.

[0025] Clean grade Sprague-D...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of small interfering RNA of long non-coding ribonucleic acid MRAK009713 to preparation of drugs for treating neuropathic pain. The small interfering RNA of the long non-coding ribonucleic acid MRAK009713 can alleviate pain behavior responses of rats with neuropathic pain, reduce P2X3 receptor expression on the dorsal root ganglion, and has the effects of preventing and treating pain. The small interfering RNA of the long non-coding ribonucleic acid MRAK009713 can further be applied to preparation of drugs for preventing and treating involved P2X3 receptor-mediated nervous system diseases. The small interfering RNA of the long non-coding ribonucleic acid MRAK009713 can be prepared into oral liquids, injections, lozenges or other preparations in local or whole body dosage forms, which are suitable for treating neuropathic pain, and preventing and treating involved P2X3 receptor-mediated nervous system diseases.

Description

technical field [0001] The present invention relates to the invention field of neuropathic pain analgesic drugs. Background technique [0002] Pain is a common symptom of most diseases, and it is an unpleasant feeling common to all human beings with great individual differences. Because pain causes great suffering to people, according to the second issue of 2001 "International Pain Society Newsletter" report: the 106th Congress of the United States passed a resolution, announcing that the ten years from January 1, 2001 will be "pain control and A decade of research". This shows that pain treatment is a difficult problem in the world. According to the pain time course, pain can be divided into acute pain (physiological pain) and chronic pain (pathological pain). Chronic pain, including inflammatory pain, neuropathic pain, and cancer pain, is one of the common clinical complaints. Due to the complex mechanism of chronic pain, its treatment has become a clinical problem. N...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K48/00A61K31/713A61P25/00
Inventor 李桂林祝高春梁尚栋姜怀德郑超然
Owner NANCHANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap